Trust Company of Vermont’s Lineage Cell Therapeutics LCTX Stock Holding History

Trust Company of Vermont’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$2.59K	Hold	1,553	–	–	﹤0.01%	1020
2025 Q3	$2.63K	Hold	1,553	–	–	﹤0.01%	996
2025 Q2	$1.41K	Hold	1,553	–	–	﹤0.01%	1024
2025 Q1	$701	Hold	1,553	–	–	﹤0.01%	988
2024 Q4	$780	Hold	1,553	–	–	﹤0.01%	998
2024 Q3	$1.41K	Buy	+1,553	New	+$1.44K	﹤0.01%	976
2022 Q4	–	Sell	-2,079	Closed	-$2K	–	937
2022 Q3	$2K	Buy	+2,079	New	+$3.05K	﹤0.01%	926

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trust Company of Vermont's LCTX Position: Q4 2025 in Review

Trust Company of Vermont held its Lineage Cell Therapeutics (LCTX) position steady in Q4 2025 at 1,553 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1020.

Trust Company of Vermont first reported a position in LCTX in Q3 2022 and has held it in 7 quarters since. The position peaked at $2.63K in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

Trust Company of Vermont held 1,553 shares of Lineage Cell Therapeutics worth $2.59K as of Q4 2025.
Trust Company of Vermont left its Lineage Cell Therapeutics share count unchanged in Q4 2025.
Lineage Cell Therapeutics made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #1020 holding.
Trust Company of Vermont first reported a position in Lineage Cell Therapeutics in Q3 2022 and has held it in 7 quarters since.
Trust Company of Vermont's Lineage Cell Therapeutics position peaked at $2.63K in Q3 2025.
123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.